Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 1:48 PM ET


Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of ...

1555 Bayshore Highway

Suite 200

Burlingame, CA 94010

United States

Founded in 2012

43 Employees



Key Executives for Kindred Biosciences, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secretary
Age: 48
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice President of Regulatory Affairs & Quality
Age: 64
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

Kindred Biosciences, Inc. Key Developments

Kindred Biosciences Announces Results from Pivotal Study of Kind-012 for Pyrexia in Horses

Kindred Biosciences, Inc. announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses. This study, KB0120, was a multicenter, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of KIND-012. The primary endpoint was improvement (a 2°F or greater decrease in temperature from baseline) or resolution of fever (a return to normothermia (=101.0°F)) at hour 6 following treatment. The success rate was approximately 75% in the KIND-012 group vs. approximately 20% in the placebo group (p < 0.0001). Based on preliminary review of the safety data, the drug appears to be well tolerated. KindredBio has already completed the in-life portion of the target animal safety study successfully and is currently preparing the chemistry, manufacturing, and controls technical section of the new animal drug application. The company plans to file the effectiveness technical section with the data from the KIND-012 pivotal field study with FDA in First Quarter 2016. The company also announced that its pivotal field study (KB090) of SentiKind for the control of pain following orthopedic surgery in dogs did not meet its primary endpoint. The data are in the process of being fully analyzed to determine next steps for this program. KindredBio also announced that results from the pivotal study of KIND-010 for management of weight loss in cats are expected by middle of 2016. KindredBio has completed a placebo-controlled, blinded pilot study of KIND-010 with positive results (p<0.05). The primary endpoint for the pivotal study is percent change in body weight. KindredBio also announced that it will be initiating a pilot field study of feline epo early 2016, on the heels of a positive laboratory pilot feline epo pilot study. The primary endpoint for the feline epo program is expected to be hematocrit or hemoglobin levels.

Kindred Biosciences, Inc. - Special Call

Kindred Biosciences, Inc. - Special Call

Kindred Biosciences, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Kindred Biosciences, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of USD 7,128,000 against USD 6,097,000 a year ago. Interest income was USD 33,000 against USD 25,000 a year ago. Net loss was USD 7,095,000 against USD 6,072,000 a year ago. Basic and diluted net loss per share was USD 0.36 against USD 0.31 a year ago. For the nine months, the company reported loss from operations of USD 20,802,000 against USD 20,417,000 a year ago. Interest income was USD 92,000 against USD 67,000 a year ago. Net loss was USD 20,710,000 against USD 20,350,000 a year ago. Basic and diluted net loss per share was USD 1.05 against USD 1.10 a year ago.

Similar Private Companies By Industry

Company Name Region
Abeome Corporation United States
ZymoChem, Inc. United States
Remedyne Corporation United States
Chemogen, Inc. United States
Intensity Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kindred Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at